Old Chang Kee's (SGX:5ML) profit for the fiscal second half ended March 31 fell by 12% to SG$4.5 million from SG$5.1 million a year earlier, according to a Friday filing with the Singapore Exchange.
Earnings per share dropped to SG$0.0374 compared with SG$0.0422 in the year-ago period.
The food and beverage company's revenue inched up 2.8% year over year to SG$51.5 million from SG$50.1 million.
Hanmi Pharm (KRX:128940) granted Eli Lilly worldwide exclusive rights to develop, produce, and market the South Korean drug company's sonefpeglutide biologic drug candidate, according to a Monday news release in Seoul.The rights do not cover Korea, according to Hanmi.Hanmi is set to receive a $75 million upfront payment from the U.S. drug company and an additional $1.19 billion in milestone payments from clinical development, regulatory approval, and commercialization.The South Korean drug company will also be eligible for royalties following the launch.Sonefpeglutide is a long-acting glucagon-like peptide 2 or GLP-2 that helps with intestinal growth. GLP-2 obtained approval for short bowel syndrome.Shares rose 6% during afternoon trading on Monday.
Azeus Systems' (SGX:BBW) profit declined 27% during the fiscal second half ended March 31 to HK$86.4 million from HK$118.1 million a year earlier, according to a Sunday filing with the Singapore Exchange.Shares of the software engineering company were down under 1% in Monday trading.Revenue fell 8% year over year to HK$281.3 million from HK$305.5 million.
Guangdong Taienkang Pharmaceutical (SHE:301263) said its Phase IIa clinical trial for CKBA Cream in treating papulopustular rosacea has completed enrollment of all 15 subjects, with positive preliminary data prompting early initiation of Phase IIb.The trial showed significant inflammatory lesion reduction after eight weeks and no serious adverse reactions, according to a Monday filing with the Shenzhen bourse.Shares of the drugmaker rose 1% in recent trade.